Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

Core Viewpoint - Conduit Pharmaceuticals Inc. has received approval from Nasdaq to transfer its common stock listing to The Nasdaq Capital Market, effective May 23, 2025, following compliance with necessary requirements [1]. Company Overview - Conduit Pharmaceuticals is a clinical stage life science company that employs an efficient model for compound development, focusing on acquiring and funding Phase 2-ready assets [2]. - The company utilizes a platform-driven approach powered by artificial intelligence (AI) and cybernetics, aiming for exits through third-party license deals after successful clinical trials [2]. - The leadership team includes experienced executives such as Dr. Andrew Regan and Dr. Freda Lewis-Hall, marking a shift from traditional pharma/biotech business models [2].